Chimerix Reports Incentive Grants Pursuant to Nasdaq Listing Rule 5635(c)(4)

DURHAM, NC, Aug. 30, 2024 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX) today announced that on August 20, 2024, the Compensation Committee of the Board of Directors of Chimerix granted a new employee an award in the form of non-statutory stock options to purchase up to 150,000 shares of Chimerix common stock. The Compensation Committee of the Board of Directors of Chimerix approved the award as an incentive for the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The exercise price per share of the stock options will be equal to Chimerix's closing share price on the grant date. The stock options have a term of 10 years and vest over four years, with one quarter vesting on the first anniversary of the termination date and the remaining three quarters vesting in equal monthly installments over the following three years. The stock options are subject to the terms of Chimerix's 2024 Equity Incentive Plan but were granted outside of the 2024 Equity Incentive Plan.

Chimerix is ​​a biopharmaceutical company committed to developing medicines that significantly improve and prolong the lives of patients with terminal diseases. The company's lead clinical development program, ONC201, is being developed for H3 K27M-mutated glioma. The company is conducting Phase 1 dose-escalation studies of ONC206 to evaluate safety and PK data.

CONTACTS:
Will O’Connor
Stern Investor Relations
212-362-1200
[email protected]
[email protected]